NKCx Histopathological outcome* within 12 months after cervix cytology in 2018 |
271 Karlskrona |
Benign | CIN1 | CIN2 | CIN3 | AIS | Cancer | Other | PAD missing | Total | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cytology | Count | Pct | Count | Pct | Count | Pct | Count | Pct | Antal | Andel | Count | Pct | Count | Pct | Count | Pct | Count | Pct |
Benign sample | 46 | 0.6% | 1 | 0.0% | . | . | . | . | . | . | . | . | . | . | 8272 | 99.4% | 8319 | 100.0% |
ASCUS | 13 | 10.9% | 25 | 21.0% | . | . | 12 | 10.1% | 1 | 0.8% | . | . | . | . | 68 | 57.1% | 119 | 100.0% |
CIN1 | 23 | 16.4% | 39 | 27.9% | . | . | 31 | 22.1% | . | . | . | . | 1 | 0.7% | 46 | 32.9% | 140 | 100.0% |
Atypical glandular cells/AGC | . | . | . | . | . | . | 1 | 100.0% | . | . | . | . | . | . | . | . | 1 | 100.0% |
ASC-H | 1 | 7.1% | 3 | 21.4% | . | . | 7 | 50.0% | . | . | 1 | 7.1% | . | . | 2 | 14.3% | 14 | 100.0% |
CIN3 | 1 | 1.9% | 6 | 11.3% | . | . | 43 | 81.1% | 2 | 3.8% | 1 | 1.9% | . | . | . | . | 53 | 100.0% |
Adenocarcinoma | . | . | . | . | . | . | . | . | 1 | 100.0% | . | . | . | . | . | . | 1 | 100.0% |
Total | 84 | 1.0% | 74 | 0.9% | . | . | 94 | 1.1% | 4 | 0.0% | 2 | 0.0% | 1 | 0.0% | 8388 | 97.0% | 8647 | 100.0% |
NOTE: Histopathological outcome from T83x taken into account. |
This list includes only one diagnosis (the highest ranking) per person, applies to both Cyt and Pad. |
* Harmonization of PAD codes classification between analysis registry and process registry has been carried out. PAD Class 0 (non diagnostic, unreasonable diagnosis) is excluded, and next PAD counts instead. |
The classes 2a, b, c and 3a (suspected premalignant, pre-malignant UNS, HPV, suspected malignant) are grouped into 'Other'. |
Process Registry's Class 1 (benign), 2d (CIN1) and 3b (manifest cancer) have all been introduced without exception. Some codes that occur beyond the scope of the process registry has been added to the different categories. |
Snomed codes in the category Cancer: |
---|
M80703 |